1 / 24

1 University of Chicago Medical Center, Chicago IL 2 US Oncology Research, Tyler, TX

A Placebo-Controlled, Randomized Phase 2 Study of Conatumumab (C) or AMG 479 (A) or Placebo (P) + Gemcitabine (G) in Patients (pts) With Metastatic Pancreatic Cancer ( mPC ).

vidar
Download Presentation

1 University of Chicago Medical Center, Chicago IL 2 US Oncology Research, Tyler, TX

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. A Placebo-Controlled, Randomized Phase 2 Study of Conatumumab (C) or AMG 479 (A) or Placebo (P) + Gemcitabine (G) in Patients (pts) With Metastatic Pancreatic Cancer (mPC) HL Kindler,1 D Richards,2 J Stephenson,3L Garbo,4 C Rocha Lima,5 H Safran,6 J Wiezorek,7 E Feigal,7 SL Bray,8 CS Fuchs9 1University of Chicago Medical Center, Chicago IL 2US Oncology Research, Tyler, TX 3Greenville Hospital System, Greenville, SC 4New York Oncology Hematology, P.C. Albany, Albany, NY 5University of Miami, Sylvester Comprehensive Cancer Center, Miami, FL 6Rhode Island Hospital, Providence, RI 7Amgen Inc., Thousand Oaks, CA 8Amgen Ltd, Cambridge, UK 9Dana-Farber Cancer Institute, Boston, MA Abstract #4035

  2. BACKGROUNDThe DR5/TRAIL Pathway in Pancreatic Cancer • Pancreatic tumors express higher levels of death receptor 5 (DR5) than normal pancreas1 • Mutations in KRAS are found in > 90% of pancreatic cancer (PC)2 • Transformation by RAS sensitizes cells to TRAIL-induced apoptosis3,4 • Conatumumab (AMG 655) is an investigational, fully human, monoclonal antibody agonist of DR5 • Binds DR5, activates caspases, and induces apoptosis5 • In mouse models of PC, conatumumab demonstrated single-agent activity, which was enhanced in combination with gemcitabine5 • In a phase 1b study in metastatic PC patients, conatumumab appeared safe in combination with gemcitabine6 • Disease control rate (partial response [PR] + stable disease [SD]) = 69%; 6-month overall survival (OS) = 76%

  3. BACKGROUNDThe DR5/TRAIL Pathway in Pancreatic Cancer

  4. BACKGROUNDThe Type 1 Insulin-Like Growth Factor Receptor (IGF-1R) Pathway and Pancreatic Cancer • IGF1-R, IGF-1, and IGF-2 are over-expressed in PC cells and tumors • Risk of PC increases in patients with increased pathway activity (insulin sensitivity, Akt2 amplification, and low serum IGFBP-1) • Pharmacological and genetic blockade of IGF-1R activity inhibits the growth of multiple PC xenograft models (alone and in combination with gemcitabine) • Tumors driven by KRAS remain sensitive to IGF-1R inhibition7-9 • AMG 479 is an investigational, fully human, monoclonal antibody antagonist of IGF-1R • Blocks binding of IGF-1 and IGF-2 to IGF-1R8 • In mouse models of PC, AMG 479 demonstrated single-agent activity; activity was enhanced in combination with gemcitabine8 • In a phase 1b study in patients with advanced solid tumors, AMG 479 appeared safe in combination with gemcitabine10

  5. BACKGROUNDThe Type 1 Insulin-Like Growth Factor Receptor (IGF-1R) Pathway and Pancreatic Cancer

  6. STUDY RATIONALE • Current therapies for PC are inadequate: novel approaches are required • Preclinical and phase I data support the evaluation of conatumumab and AMG 479 in PC patients • Randomized phase II studies may be superior to single-arm trials in evaluating novel agents in PC • Therefore, a 3-arm, placebo-controlled, randomized phase 2 study was conducted to evaluate conatumumab + gemcitabine and AMG 479 + gemcitabine versus placebo + gemcitabine in metastatic PC patients

  7. PRIMARY ENDPOINT • 6-month OS rate

  8. METHODSStudy Schema aThe AMG 479 + gemcitabine arm was open label due to anticipated thrombocytopenia and hyperglycemia.

  9. METHODSSecondary Endpoints • Response rate (by RECIST) • Investigator defined, no central review • Progression-free survival (PFS, investigator defined) • OS • Incidence of adverse events (AE) and laboratory abnormalities • Incidence of anti-conatumumab or anti-AMG 479 antibodies • Pharmacokinetics of conatumumab and AMG 479 • Dose intensity of gemcitabine when combined with conatumumab, AMG 479, or placebo

  10. METHODSKey Inclusion Criteria • Histologically or cytologically documented metastaticadenocarcinoma of the pancreas • ≥ 18 years of age • ECOG PS 0 or 1 • Adequate hematologic, hepatic, renal, and coagulation function • Amylase and lipase ≤ 2.0 x ULN • Adequately controlled type 1 or 2 diabetes (amended during study to FBS <160 mg/dL only) • Fasting blood sugar ≤ 160 mg/dL • HbA1c < 8% • Written informed consent

  11. METHODSKey Exclusion Criteria • Uncontrolled cardiac disease • Prior chemotherapy or radiation in the adjuvant or metastatic setting

  12. METHODSStatistics • The study was designed as an estimation study • Planned sample size of 120 (40/arm) • As designed (estimation, not hypothesis-testing), the trial has 80% power to detect a difference between a 6-month OS rate of: • 45% for placebo • 69% for conatumumab or AMG 479 (target improvement, 10%)

  13. RESULTSBaseline Demographics

  14. RESULTSBaseline Lesion Sites

  15. RESULTSEfficacy aPrimary endpoint. HR, hazard ratio; CI, confidence interval. • The PFS and OS results were robust after adjusting for baseline covariates (age, gender, ECOG PS status, liver metastases, and tumor sum of longest diameter)

  16. RESULTSProgression-Free Survival Full analysis set. aStratified hazard ratio (estimates relative to placebo + gemcitabine arm). bStratified log-rank test.HR, hazard ratio; KM, Kaplan-Meier; CI, confidence interval.

  17. RESULTSOverall Survival Full analysis set. aStratified hazard ratio (estimates relative to placebo + gemcitabine arm). bStratified log-rank test.

  18. RESULTSBest Overall Tumor Response CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease.

  19. RESULTSGrade 3-5 Adverse Eventsa aIn ≥ 5% of patients. bOne GI perforation, 1 GI hemorrhage,1 hepatic failure in a patient with liver metastases, 4 PD. cOne acute renal failure, 1 hemorrhage, 2 PD. dOne GI hemorrhage.

  20. RESULTSDrug Exposure aRatio of cumulative dose of drug : protocol-specified cumulative dose over the specified period. IP, investigational product.

  21. CONCLUSIONS • This randomized phase 2 study shows evidence of activity for AMG 479 with trends across several efficacy parameters in metastatic PC • Improved 6-month OS rate (primary endpoint) (57% vs 50%) • Improved 12-month OS (39% vs 23%) • Longer PFS (5.1 vs 2.1 months, HR 0.65) • Longer OS (8.7 vs 5.9 months, HR 0.67) • Higher rates of SD + PR (51% vs 41%)

  22. CONCLUSIONS (continued) • The study also shows evidence of activity for conatumumab • Improved 6-month OS rate (primary endpoint) (59% vs. 50%) • Longer PFS (4.0 vs 2.1 months, HR 0.65) • Higher rates of SD + PR (61% vs 41%) • Both drug combinations were well-tolerated • These data suggest that further study of AMG 479 + gemcitabine is warranted in advanced PC

  23. REFERENCES 1. Data on file. Amgen Inc. 2. Koorstra JB, et al. Pancreatology. 2008;8:110-125. 3. Nesterov AM, et al. Cancer Res. 2004;64:3922-3927. 4. Drosopoulos KG, et al. J Biol Chem. 2005;280:22856-22867. 5. Kaplan-Lefko PJ, et al. Cancer BiolTher. 2010;9:618-631. 6. Kindler HL, et al. J ClinOncol. 2009;27:abstr 4501. 7. Beltran PJ, et al. Mol Cancer Ther. 2009;8:1095-1105. 8. Sell C, et al. Mol Cell Biol. 1994;14:3604-3612. 9. Yeh AH, et al. Oncogene. 2006;25:6574-6581. 10. Sarantopoulos J, et al. J ClinOncol. 2008;26:abstr 3583.

  24. ACKNOWLEDGMENTS • This study was sponsored by Amgen Inc. (ClinicalTrials.gov: NCT00630552)

More Related